Addex Therapeutics Ltd
ADXNHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeAddex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The $4.7M market capitalization puts ADXN squarely in micro-cap range for its industry. The company focuses on the discovery of G-protein coupled receptors and enzymes.
Market Cap
$4.7M
Beta
1.96
P/E (TTM)
—
P/E (Fwd)
-74.00
EPS (TTM)
$-8.86
EPS (Fwd)
$-0.05
ROE
-122.3%
ROA
-23.6%
Cash
$935,153
Total Debt
$102,269
Free CF
-$1.5M
52W Change
-52.9%
Annual Financials
Cash vs Debt
Where ADXN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ADXN finished 44.83% below its 150-day moving average ($6.38) and 48.16% below its 200-day moving average ($6.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ADXN overbought or oversold?
At the September 3, 2026 close, ADXN's RSI(14) was 19.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Addex Therapeutics Ltd holds $935K in cash against $102K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$1.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -122.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $1.4M (2022) to $30K (2025), a 98% decline worth watching.
With a beta above 1.5, ADXN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Addex Therapeutics Ltd and its sector.